Dendritic Cell Vaccines

  • Sylvia Adams
  • Nina Bhardwaj
  • David W. O’Neill


Dendritic Cell Major Histocompatibility Complex Major Histocompatibility Complex Class Metastatic Melanoma Antitumor Immunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McKenna, K., A.S. Beignon, and N. Bhardwaj, Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol, 2005. 79(1): p. 17–27.PubMedGoogle Scholar
  2. 2.
    Shortman, K. and Y.J. Liu, Mouse and human dendritic cell subtypes. Nat Rev Immunol, 2002. 2(3): p. 151–61.PubMedGoogle Scholar
  3. 3.
    Ebner, S., et al., Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int Immunol, 2004. 16(6): p. 877–87.PubMedGoogle Scholar
  4. 4.
    Rafiq, K., A. Bergtold, and R. Clynes, Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest, 2002. 110(1): p. 71–9.PubMedGoogle Scholar
  5. 5.
    Albert, M.L., et al., Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med, 1998. 188(7): p. 1359–68.PubMedGoogle Scholar
  6. 6.
    Bonifaz, L., et al., Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med, 2002. 196(12): p. 1627–38.PubMedGoogle Scholar
  7. 7.
    Peiser, L., S. Mukhopadhyay, and S. Gordon, Scavenger receptors in innate immunity. Curr Opin Immunol, 2002. 14(1): p. 123–8.PubMedGoogle Scholar
  8. 8.
    Basu, S., et al., CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity, 2001. 14(3): p. 303–13.PubMedGoogle Scholar
  9. 9.
    Delneste, Y., et al., Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity, 2002. 17(3): p. 353–62.PubMedGoogle Scholar
  10. 10.
    Guermonprez, P., et al., Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol, 2002. 20: p. 621–67.PubMedGoogle Scholar
  11. 11.
    Chow, A., et al., Dendritic cell maturation triggers retrograde MHC class II transport from lysosomes to the plasma membrane. Nature, 2002. 418(6901): p. 988–94.PubMedGoogle Scholar
  12. 12.
    Guermonprez, P., et al., ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature, 2003. 425(6956): p. 397–402.PubMedGoogle Scholar
  13. 13.
    Fonteneau, J.F., M. Larsson, and N. Bhardwaj, Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr Opin Immunol, 2002. 14(4): p. 471–7.PubMedGoogle Scholar
  14. 14.
    Ackerman, A.L., et al., Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci U S A, 2003. 100(22): p. 12889–94.PubMedGoogle Scholar
  15. 15.
    Houde, M., et al., Phagosomes are competent organelles for antigen cross-presentation. Nature, 2003. 425(6956): p. 402–6.PubMedGoogle Scholar
  16. 16.
    Lizee, G., et al., Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol, 2003. 4(11): p. 1065–73.PubMedGoogle Scholar
  17. 17.
    Wolkers, M.C., et al., Antigen bias in T cell cross-priming. Science, 2004. 304(5675): p. 1314–7.PubMedGoogle Scholar
  18. 18.
    Moody, D.B. and S.A. Porcelli, Intracellular pathways of CD1 antigen presentation. Nat Rev Immunol, 2003. 3(1): p. 11–22.PubMedGoogle Scholar
  19. 19.
    Joyce, S. and L. Van Kaer, CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol, 2003. 15(1): p. 95–104.PubMedGoogle Scholar
  20. 20.
    Fujii, S., et al., Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol, 2002. 3(9): p. 867–74.PubMedGoogle Scholar
  21. 21.
    Fujimoto, Y., et al., CD83 expression influences CD4+ T cell development in the thymus. Cell, 2002. 108(6): p. 755–67.PubMedGoogle Scholar
  22. 22.
    Lechmann, M., et al., CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol, 2002. 23(6): p. 273–5.PubMedGoogle Scholar
  23. 23.
    Matzinger, P., The danger model: a renewed sense of self. Science, 2002. 296(5566): p. 301–5.PubMedGoogle Scholar
  24. 24.
    Skoberne, M., A.S. Beignon, and N. Bhardwaj, Danger signals: a time and space continuum. Trends Mol Med, 2004. 10(6): p. 251–7.PubMedGoogle Scholar
  25. 25.
    Cheng, F., et al., A critical role for Stat3 signaling in immune tolerance. Immunity, 2003. 19(3): p. 425–36.PubMedGoogle Scholar
  26. 26.
    Kadowaki, N., et al., Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med, 2001. 194(6): p. 863–9.PubMedGoogle Scholar
  27. 27.
    Hornung, V., et al., Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol, 2002. 168(9): p. 4531–7.PubMedGoogle Scholar
  28. 28.
    Jarrossay, D., et al., Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol, 2001. 31(11): p. 3388–93.PubMedGoogle Scholar
  29. 29.
    Delamarre, L., et al., Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science, 2005. 307(5715): p. 1630–4.PubMedGoogle Scholar
  30. 30.
    Delamarre, L., H. Holcombe, and I. Mellman, Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med, 2003. 198(1): p. 111–22.PubMedGoogle Scholar
  31. 31.
    Datta, S.K., et al., A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol, 2003. 170(8): p. 4102–10.PubMedGoogle Scholar
  32. 32.
    Shin, T., et al., Cooperative B7–1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med, 2003. 198(1): p. 31–8.PubMedGoogle Scholar
  33. 33.
    Nguyen, L.T., et al., Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med, 2002. 196(10): p. 1393–8.PubMedGoogle Scholar
  34. 34.
    Suh, W.K., et al., The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol, 2003. 4(9): p. 899–906.PubMedGoogle Scholar
  35. 35.
    Zang, X., et al., B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A, 2003. 100(18): p. 10388–92.PubMedGoogle Scholar
  36. 36.
    Colonna, M., TREMs in the immune system and beyond. Nat Rev Immunol, 2003. 3(6): p. 445–53.PubMedGoogle Scholar
  37. 37.
    Kolb-Maurer, A., et al., Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol Med Microbiol, 2003. 35(3): p. 255–62.PubMedGoogle Scholar
  38. 38.
    Dzionek, A., et al., BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med, 2001. 194(12): p. 1823–34.PubMedGoogle Scholar
  39. 39.
    Randolph, G.J., G. Sanchez-Schmitz, and V. Angeli, Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol, 2004.Google Scholar
  40. 40.
    Ohl, L., et al., CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity, 2004. 21(2): p. 279–88.PubMedGoogle Scholar
  41. 41.
    Steinman, R.M. and M.C. Nussenzweig, Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A, 2002. 99(1): p. 351–8.PubMedGoogle Scholar
  42. 42.
    Dhodapkar, M.V., et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med, 2001. 193(2): p. 233–8.PubMedGoogle Scholar
  43. 43.
    Banchereau, J., et al., Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res, 2001. 61(17): p. 6451–8.PubMedGoogle Scholar
  44. 44.
    Adams, S., D. O’Neill, and N. Bhardwaj, Maturation matters: importance of maturation for antitumor immunity of dendritic cell vaccines. J Clin Oncol, 2004. 22(18): p. 3834–5; author reply 3835.PubMedGoogle Scholar
  45. 45.
    Mossman, K.D., et al., Altered TCR signaling from geometrically repatterned immunological synapses. Science, 2005. 310(5751): p. 1191–3.PubMedGoogle Scholar
  46. 46.
    Stoll, S., et al., Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science, 2002. 296(5574): p. 1873–6.PubMedGoogle Scholar
  47. 47.
    Bousso, P. and E. Robey, Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol, 2003. 4(6): p. 579–85.PubMedGoogle Scholar
  48. 48.
    Gett, A.V., et al., T cell fitness determined by signal strength. Nat Immunol, 2003. 4(4): p. 355–60.PubMedGoogle Scholar
  49. 49.
    van Stipdonk, M.J., et al., Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol, 2003. 4(4): p. 361–5.PubMedGoogle Scholar
  50. 50.
    Tato, C.M., A. Laurence, and J.J. O’Shea, Helper T cell differentiation enters a new era: le roi est mort; vive le roi! J Exp Med, 2006. 203(4): p. 809–12.PubMedGoogle Scholar
  51. 51.
    Akbari, O., R.H. DeKruyff, and D.T. Umetsu, Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol, 2001. 2(8): p. 725–31.PubMedGoogle Scholar
  52. 52.
    Mora, J.R., et al., Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature, 2003. 424(6944): p. 88–93.PubMedGoogle Scholar
  53. 53.
    Hoebe, K., et al., Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature, 2003. 424(6950): p. 743–8.PubMedGoogle Scholar
  54. 54.
    Weiner, H.L., The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol, 2001. 2(8): p. 671–2.PubMedGoogle Scholar
  55. 55.
    Shedlock, D.J. and H. Shen, Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science, 2003. 300(5617): p. 337–9.PubMedGoogle Scholar
  56. 56.
    Karsunky, H., et al., Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med, 2003. 198(2): p. 305–13.PubMedGoogle Scholar
  57. 57.
    Schoenberger, S.P., et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 1998. 393(6684): p. 480–3.PubMedGoogle Scholar
  58. 58.
    Croft, M., Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol, 2003. 3(8): p. 609–20.PubMedGoogle Scholar
  59. 59.
    Rogers, P.R., et al., OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity, 2001. 15(3): p. 445–55.PubMedGoogle Scholar
  60. 60.
    Janssen, E.M., et al., CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature, 2005. 434(7029): p. 88–93.PubMedGoogle Scholar
  61. 61.
    Thurner, B., et al., Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods, 1999. 223(1): p. 1–15.PubMedGoogle Scholar
  62. 62.
    O’Neill, D. and N. Bhardwaj, Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol Med, 2005. 109: p. 97–112.PubMedGoogle Scholar
  63. 63.
    Hsu, F.J., et al., Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med, 1996. 2(1): p. 52–8.PubMedGoogle Scholar
  64. 64.
    Kiertscher, S.M., et al., Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients. Int J Cancer, 2003. 107(2): p. 256–61.PubMedGoogle Scholar
  65. 65.
    Slingluff, C., et al., Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. J. Clin. Oncol., 2003(November): p. 4016–4026.Google Scholar
  66. 66.
    Jonuleit, H., et al., A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer, 2001. 93(2): p. 243–51.PubMedGoogle Scholar
  67. 67.
    Jonuleit, H., et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 1997. 27(12): p. 3135–42.PubMedGoogle Scholar
  68. 68.
    Sato, E., et al., Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 2005. 102(51): p. 18538–43.PubMedGoogle Scholar
  69. 69.
    Dave, S.S., et al., Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 2004. 351(21): p. 2159–69.PubMedGoogle Scholar
  70. 70.
    Hanada, K., J.W. Yewdell, and J.C. Yang, Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature, 2004. 427(6971): p. 252–6.PubMedGoogle Scholar
  71. 71.
    Vigneron, N., et al., An antigenic peptide produced by peptide splicing in the proteasome. Science, 2004. 304(5670): p. 587–90.PubMedGoogle Scholar
  72. 72.
    Warren, E.H., et al., An antigen produced by splicing of noncontiguous peptides in the reverse order. Science, 2006. 313(5792): p. 1444–7.PubMedGoogle Scholar
  73. 73.
    Simpson, A.J., et al., Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 2005. 5(8): p. 615–25.PubMedGoogle Scholar
  74. 74.
    Schuler-Thurner, B., et al., Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide- loaded monocyte-derived dendritic cells. J Exp Med, 2002. 195(10): p. 1279–88.PubMedGoogle Scholar
  75. 75.
    Nestle, F.O., et al., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med, 1998. 4(3): p. 328–32.PubMedGoogle Scholar
  76. 76.
    Dhodapkar, M.V., et al., Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest, 1999. 104(2): p. 173–80.PubMedGoogle Scholar
  77. 77.
    Fong, L., et al., Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A, 2001. 98(15): p. 8809–14.PubMedGoogle Scholar
  78. 78.
    Wang, R.F. and H.Y. Wang, Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol, 2002. 20(2): p. 149–54.PubMedGoogle Scholar
  79. 79.
    Berzofsky, J.A., J.D. Ahlers, and I.M. Belyakov, Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol, 2001. 1(3): p. 209–19.PubMedGoogle Scholar
  80. 80.
    Timmerman, J.M., et al., Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood, 2002. 99(5): p. 1517–26.PubMedGoogle Scholar
  81. 81.
    Heiser, A., et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 2002. 109(3): p. 409–17.PubMedGoogle Scholar
  82. 82.
    Engelmayer, J., et al., Mature dendritic cells infected with canarypox virus elicit strong anti- human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol, 2001. 75(5): p. 2142–53.PubMedGoogle Scholar
  83. 83.
    Dietz, A.B. and S. Vuk-Pavlovic, High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood, 1998. 91(2): p. 392–8.PubMedGoogle Scholar
  84. 84.
    Su, Z., et al., Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res, 2003. 63(9): p. 2127–33.PubMedGoogle Scholar
  85. 85.
    Thumann, P., et al., Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods, 2003. 277(1–2): p. 1–16.PubMedGoogle Scholar
  86. 86.
    Parkhurst, M.R., et al., Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J Immunol, 2003. 170(10): p. 5317–25.PubMedGoogle Scholar
  87. 87.
    Morse, M.A., et al., Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res, 1999. 59(1): p. 56–8.PubMedGoogle Scholar
  88. 88.
    Mackensen, A., et al., Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother, 1999. 48(2–3): p. 118–22.PubMedGoogle Scholar
  89. 89.
    Mullins, D.W., et al., Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. J Exp Med, 2003. 198(7): p. 1023–34.PubMedGoogle Scholar
  90. 90.
    Fong, L., et al., Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol, 2001. 166(6): p. 4254–9.PubMedGoogle Scholar
  91. 91.
    Ridolfi, R., et al., Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med, 2004. 2(1): p. 27.PubMedGoogle Scholar
  92. 92.
    Nair, S., et al., Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol, 2003. 171(11): p. 6275–82.PubMedGoogle Scholar
  93. 93.
    Suzuki, H., et al., Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000. 114(1): p. 135–41.PubMedGoogle Scholar
  94. 94.
    Badovinac, V.P., et al., Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med, 2005. 11(7): p. 748–56.PubMedGoogle Scholar
  95. 95.
    Ridgway, D., The first 1000 dendritic cell vaccinees. Cancer Invest, 2003. 21(6): p. 873–86.PubMedGoogle Scholar
  96. 96.
    Therasse, P., et al., New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000. 92(3): p. 205–16.PubMedGoogle Scholar
  97. 97.
    Schadendorf, D., et al., Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol, 2006. 17(4): p. 563–70.PubMedGoogle Scholar
  98. 98.
    Holtl, L., et al., Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res, 2002. 8(11): p. 3369–76.PubMedGoogle Scholar
  99. 99.
    O’Rourke, M.G., et al., Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother, 2003. 52(6): p. 387–95.PubMedGoogle Scholar
  100. 100.
    Maier, T., et al., Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood, 2003. 102(7): p. 2338–44.PubMedGoogle Scholar
  101. 101.
    Antonia, S.J., et al., Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 2006. 12(3 Pt 1): p. 878–87.PubMedGoogle Scholar
  102. 102.
    Arnould, L., et al., Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer, 2006. 94(2): p. 259–67.PubMedGoogle Scholar
  103. 103.
    Babatz, J., et al., Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother, 2006. 55(3): p. 268–76.PubMedGoogle Scholar
  104. 104.
    Di Pucchio, T., et al., Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res, 2006. 66(9): p. 4943–51.PubMedGoogle Scholar
  105. 105.
    Fuessel, S., et al., Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate, 2006. 66(8): p. 811–21.PubMedGoogle Scholar
  106. 106.
    Lou, E., et al., A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer, 2006. 5(5): p. 368–71.PubMedGoogle Scholar
  107. 107.
    Loveland, B.E., et al., Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res, 2006. 12(3 Pt 1): p. 869–77.PubMedGoogle Scholar
  108. 108.
    Perambakam, S., et al., Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146–154 peptide. Cancer Immunol Immunother, 2006. 55(9): p. 1033–42.PubMedGoogle Scholar
  109. 109.
    Thomas-Kaskel, A.K., et al., Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer, 2006.Google Scholar
  110. 110.
    Trakatelli, M., et al., A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother, 2006. 55(4): p. 469–74.PubMedGoogle Scholar
  111. 111.
    Tuettenberg, A., et al., Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer, 2006. 118(10): p. 2617–27.PubMedGoogle Scholar
  112. 112.
    Wierecky, J., M. Mueller, and P. Brossart, Dendritic cell-based cancer immunotherapy targeting MUC-1. Cancer Immunol Immunother, 2006. 55(1): p. 63–7.PubMedGoogle Scholar
  113. 113.
    Osada, T., et al., NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother, 2006. 55(9): p. 1122–31.PubMedGoogle Scholar
  114. 114.
    Wilson, N.S., et al., Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol, 2006. 7(2): p. 165–72.PubMedGoogle Scholar
  115. 115.
    Dillon, S., et al., Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest, 2006. 116(4): p. 916–28.PubMedGoogle Scholar
  116. 116.
    Su, Z., et al., Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res, 2002. 62(17): p. 5041–8.PubMedGoogle Scholar
  117. 117.
    Merad, M., et al., In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood, 2002. 99(5): p. 1676–82.PubMedGoogle Scholar
  118. 118.
    Cho, H.J., et al., Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol, 2000. 18(5): p. 509–14.PubMedGoogle Scholar
  119. 119.
    Schneeberger, A., et al., CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol, 2004. 123(2): p. 371–9.PubMedGoogle Scholar
  120. 120.
    Weeratna, R.D., et al., TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine, 2005. 23(45): p. 5263–70.PubMedGoogle Scholar
  121. 121.
    Wille-Reece, U., et al., Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol, 2005. 174(12): p. 7676–83.PubMedGoogle Scholar
  122. 122.
    Itoh, T. and E. Celis, Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother, 2005. 28(5): p. 430–7.PubMedGoogle Scholar
  123. 123.
    Klinman, D.M., et al., Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev, 2004. 199: p. 201–16.PubMedGoogle Scholar
  124. 124.
    Speiser, D.E., et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest, 2005. 115(3): p. 739–46.PubMedGoogle Scholar
  125. 125.
    Kim, T.W., et al., Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol, 2003. 171(6): p. 2970–6.PubMedGoogle Scholar
  126. 126.
    Sudowe, S., et al., Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. Mol Ther, 2003. 8(4): p. 567–75.PubMedGoogle Scholar
  127. 127.
    Garg, S., et al., Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol, 2003. 4(9): p. 907–12.PubMedGoogle Scholar
  128. 128.
    MartIn-Fontecha, A., et al., Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med, 2003. 198(4): p. 615–21.PubMedGoogle Scholar
  129. 129.
    Belli, F., et al., Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol, 2002. 20(20): p. 4169–80.PubMedGoogle Scholar
  130. 130.
    Wang, H.Y., et al., Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest, 2002. 109(11): p. 1463–70.PubMedGoogle Scholar
  131. 131.
    Mohty, M., et al., All-trans retinoic acid skews monocyte differentiation into interleukin-12-secreting dendritic-like cells. Br J Haematol, 2003. 122(5): p. 829–36.PubMedGoogle Scholar
  132. 132.
    Adams, S., et al., PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res, 2004. 64(15): p. 5471–80.PubMedGoogle Scholar
  133. 133.
    Nefedova, Y., et al., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 2004. 172(1): p. 464–74.PubMedGoogle Scholar
  134. 134.
    Song, X.T., et al., An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med, 2006. 3(1): p. e11.PubMedGoogle Scholar
  135. 135.
    Nair, S., et al., Synergy between tumor immunotherapy and antiangiogenic therapy. Blood, 2003. 102(3): p. 964–71.PubMedGoogle Scholar
  136. 136.
    Gabrilovich, D.I., et al., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res, 1999. 5(10): p. 2963–70.PubMedGoogle Scholar
  137. 137.
    Rini, B.I., et al., Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer, 2006. 107(1): p. 67–74.PubMedGoogle Scholar
  138. 138.
    Borg, C., et al., Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest, 2004. 114(3): p. 379–88.PubMedGoogle Scholar
  139. 139.
    Ghiringhelli, F., et al., CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 2005. 202(8): p. 1075–85.PubMedGoogle Scholar
  140. 140.
    Hodi, F.S., et al., Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A, 2003. 100(8): p. 4712–7.PubMedGoogle Scholar
  141. 141.
    Phan, G.Q., et al., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A, 2003. 100(14): p. 8372–7.PubMedGoogle Scholar
  142. 142.
    Attia, P., et al., Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol, 2005. 23(25): p. 6043–53.PubMedGoogle Scholar
  143. 143.
    Beck, K.E., et al., Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol, 2006. 24(15): p. 2283–9.PubMedGoogle Scholar
  144. 144.
    Curiel, T.J., et al., Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med, 2003. 9(5): p. 562–7.PubMedGoogle Scholar
  145. 145.
    Watanabe, N., et al., BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol, 2003. 4(7): p. 670–9.PubMedGoogle Scholar
  146. 146.
    Carreno, B.M. and M. Collins, BTLA: a new inhibitory receptor with a B7-like ligand. Trends Immunol, 2003. 24(10): p. 524–7.PubMedGoogle Scholar
  147. 147.
    Francois Bach, J., Regulatory T cells under scrutiny. Nat Rev Immunol, 2003. 3(3): p. 189–98.PubMedGoogle Scholar
  148. 148.
    Jonuleit, H. and E. Schmitt, The regulatory T cell family: distinct subsets and their interrelations. J Immunol, 2003. 171(12): p. 6323–7.PubMedGoogle Scholar
  149. 149.
    Woo, E.Y., et al., Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res, 2001. 61(12): p. 4766–72.PubMedGoogle Scholar
  150. 150.
    Wolf, A.M., et al., Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res, 2003. 9(2): p. 606–12.PubMedGoogle Scholar
  151. 151.
    Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004. 10(9): p. 942–9.PubMedGoogle Scholar
  152. 152.
    Oldenhove, G., et al., CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med, 2003. 198(2): p. 259–66.PubMedGoogle Scholar
  153. 153.
    Dannull, J., et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest, 2005. 115(12): p. 3623–33.PubMedGoogle Scholar
  154. 154.
    Asavaroengchai, W., Y. Kotera, and J.J. Mule, Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A, 2002. 99(2): p. 931–6.PubMedGoogle Scholar
  155. 155.
    Rapoport, A.P., et al., Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med, 2005.Google Scholar
  156. 156.
    Dudley, M.E., et al., Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 2005. 23(10): p. 2346–57.PubMedGoogle Scholar
  157. 157.
    Gattinoni, L., et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med, 2005. 202(7): p. 907–12.PubMedGoogle Scholar
  158. 158.
    Morgan, R.A., et al., Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006.Google Scholar
  159. 159.
    Overwijk, W.W., et al., Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med, 2003. 198(4): p. 569–80.PubMedGoogle Scholar
  160. 160.
    Friedman, E.J., Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des, 2002. 8(19): p. 1765–80.PubMedGoogle Scholar
  161. 161.
    Chen, Z., et al., Combined radiation therapy and dendritic cell vaccine for treating solid tumors with liver micro-metastasis. J Gene Med, 2005. 7(4): p. 506–17.PubMedGoogle Scholar
  162. 162.
    Chi, K.H., et al., Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother, 2005. 28(2): p. 129–35.PubMedGoogle Scholar
  163. 163.
    Lake, R.A. and B.W. Robinson, Immunotherapy and chemotherapy–a practical partnership. Nat Rev Cancer, 2005. 5(5): p. 397–405.PubMedGoogle Scholar
  164. 164.
    Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996. 2(10): p. 1096–103.PubMedGoogle Scholar
  165. 165.
    Gabrilovich, D.I., et al., Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res, 1997. 3(3): p. 483–90.PubMedGoogle Scholar
  166. 166.
    Furumoto, K., et al., Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest, 2004. 113(5): p. 774–83.PubMedGoogle Scholar
  167. 167.
    Sharma, S., et al., Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN. Neoplasia, 2004. 6(5): p. 523–8.PubMedGoogle Scholar
  168. 168.
    Carpentier, A.F., et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res, 2000. 6(6): p. 2469–73.PubMedGoogle Scholar
  169. 169.
    Meng, Y., et al., Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer, 2005. 116(6): p. 992–7.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Sylvia Adams
    • 1
  • Nina Bhardwaj
    • 1
  • David W. O’Neill
    • 1
  1. 1.NYU Cancer Institute Tumor Vaccine CenterNew York University School of MedicineNew York

Personalised recommendations